Hinge Health files Rule 144 notice for 4.49M Series B

Hinge Health, Inc. notice of proposed sale of securities under Rule 144.

Rhea-AI Filing Summary

Hinge Health, Inc. notice of proposed sale of securities under Rule 144. The filing lists Common Class A and previously issued Series B Preferred Stock (noted as "Stock Conversion before IPO"), with a Series B quantity of 4,485,644 shown and transaction-related dates of 07/03/2018 and 06/16/2026.

Key Figures

Form type: 144 Exchange mention: NYSE Series B quantity: 4,485,644 shares +2 more

5 metrics

Form type 144 Rule 144 notice of proposed sale

Exchange mention NYSE Exchange noted alongside date <b>06/16/2026</b>

Series B quantity 4,485,644 shares Listed next to Series B Preferred Stock and date <b>07/03/2018</b>

Filer identifier 600613 Numeric entry present in the excerpt

Additional numeric entries 42,343,216.50; 54,655,926 Numbers appearing on the securities line in the excerpt

Key Terms

Form 144, Series B Preferred Stock, Stock Conversion before IPO, Wired to portfolio company

4 terms

Form 144 regulatory

"Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Series B Preferred Stock financial

"Series B Preferred Stock | 07/03/2018 | Stock Conversion before IPO"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Stock Conversion before IPO corporate

"Series B Preferred Stock | 07/03/2018 | Stock Conversion before IPO"

Wired to portfolio company other

"07/03/2018 | Wired to portfolio company"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the HNGE Form 144 disclose?

The filing discloses a proposed sale under Rule 144 of Common Class A and Series B Preferred Stock. It lists 4,485,644 Series B shares and dates 07/03/2018 and 06/16/2026 in the notice.

How many Series B shares are referenced in the HNGE filing?

The document shows 4,485,644 Series B Preferred Stock units. The entry appears beside the Series B line with the date 07/03/2018 in the excerpt.

Does the Form 144 state where proceeds go for Hinge Health securities?

The excerpt does not specify proceeds recipients or uses. It notes a status line "Wired to portfolio company" but does not attach an explicit proceeds description in the provided text.

What dates appear in the HNGE Form 144 excerpt?

The excerpt includes 07/03/2018 (associated with Series B) and 06/16/2026 (appearing with NYSE and security lines). These dates are shown verbatim in the content.

Is the sale completed according to this Form 144 excerpt?

This filing is a notice of a proposed sale under Rule 144. The excerpt lists securities "To Be Sold" and a prior sale line, but it does not state that any new sale has been completed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 05:24 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001710860
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Hinge Health, Inc.
SEC File Number	001-42657
Address of Issuer	455 MARKET STREET 7TH FLOOR SAN FRANCISCO CALIFORNIA 94105
Phone	415-689-8429
Name of Person for Whose Account the Securities are To Be Sold	Insight Venture Partners (Cayman) X, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Class A	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	600613	42343216.50	54655926	06/16/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Series B Preferred Stock	07/03/2018	Stock Conversion before IPO	Hinge Health, Inc.			4485644	07/03/2018	Wired to portfolio company

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	06/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Jonathan Grossman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)